Case Report: Omalizumab-Associated Hair Loss: A Case of Eyebrow Alopecia Areata, Literature Review and FAERS Database Analysis

June 2025 in “ Frontiers in Medicine ”

Qian Wang, Lei Hua, Ge Yang, Ying Li, Wei Liu, Lixia Zhang, Xiyuan Zhou

omalizumab eyebrow alopecia areata tacrolimus chronic spontaneous urticaria FAERS database alopecia Xolair

Studysummary This study observed that omalizumab may induce alopecia, particularly in females aged 18-60, though establishing a direct cause-effect link remains challenging. Alopecia areata was noted as a possible uncommon, yet transient, hair loss type associated with omalizumab.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

This case report describes a 52-year-old female who developed eyebrow alopecia areata after 12 weeks of omalizumab treatment for chronic spontaneous urticaria. Her eyebrows regrew after 28 weeks with the use of topical tacrolimus, despite continuing omalizumab. Analysis of 756 cases from the FAERS database and a literature review suggest that omalizumab may induce alopecia, particularly in females aged 18-60, although a direct cause-effect relationship is difficult to establish. Alopecia areata appears to be a less common but potentially transient side effect. The study emphasizes the need for clinicians to recognize this potential adverse effect to improve patient counseling and treatment planning.

View this study on frontiersin.org →

Discuss this study in the Community →

Research cited in this study

11 / 11 results

research Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of the Literature

10 citations , October 2024 in “Dermatology Practical & Conceptual”

This study found that dupilumab's effects on alopecia areata varied depending on patients' immune profiles, with Th2-skewed females seeing improvements and Th1-driven males experiencing worsening.

research Drug-Induced Hair Loss: Analysis of the Food and Drug Administration’s Adverse Events Reporting System Database

July 2024 in “Skin Appendage Disorders”

This study analyzed adverse event reports from the FDA database and found that drugs such as immunomodulatory agents, monoclonal antibodies, minoxidil, contraceptives, and anti-TNF drugs are frequently associated with hair loss, suggesting guidance for dermatologists in identifying common medications linked to alopecia.

research Alopecia Due to Chemotherapeutics, Hedgehog Inhibitors, Targeted Antibody Therapies, and Immune Checkpoint Inhibitors

May 2024 in “Deleted Journal”

This study reports that chemotherapy-induced hair loss affects up to 65% of patients, typically within 1 to 3 weeks of treatment, while scalp cooling may help prevent severe hair loss with taxane-based therapies.

research Deciphering the Complex Immunopathogenesis of Alopecia Areata

45 citations , May 2024 in “International Journal of Molecular Sciences”

This manuscript reviews the latest understanding of alopecia areata's pathogenesis, highlighting the roles of genetic, immunological, and environmental factors, with a focus on immune responses involving IFN-γ and cytotoxic CD8+ T-cells as key contributors to hair follicle inflammation and function disruption without follicle destruction.

research A Cross-Sectional Analysis of Medications Used by Patients Reporting Alopecia Areata on the FDA Adverse Events Reporting System

6 citations , January 2024 in “International Journal of Dermatology”

This study examined FAERS data and found an increasing trend in alopecia areata cases, with monoclonal antibodies most frequently linked to the condition.

research Drug-Induced Alopecia Areata: A Systematic Review

3 citations , May 2023 in “Journal of the American Academy of Dermatology”

This study found that drug-induced alopecia areata was most commonly associated with TNF-alpha inhibitors and dupilumab, with most cases improving after discontinuing the medication.

Comparative Evaluation of the Efficacy of Topical Tacrolimus 0.03% and Topical Calcipotriol 0.005% Mixed With Betamethasone Dipropionate Versus Topical Clobetasol 0.05% in Treatment of Alopecia Areata: A Clinical and Trichoscopic Study

research Comparative Evaluation of the Efficacy of Topical Tacrolimus 0.03% and Topical Calcipotriol 0.005% Mixed With Betamethasone Dipropionate Versus Topical Clobetasol 0.05% in Treatment of Alopecia Areata: A Clinical and Trichoscopic Study

1 citations , December 2022 in “Journal of cosmetic dermatology”

This study found that combining a potent steroid with a vitamin D analogue may offer more convenient treatment for localized alopecia areata than using a superpotent steroid alone, with comparable efficacy but fewer side effects.

research Telogen Effluvium: A Review of the Literature

40 citations , May 2020 in “Cureus”

This review discusses the causes, diagnosis, and treatment of telogen effluvium and reports no new clinical findings; the authors underscore the importance of identifying and eliminating causative factors.